SlideShare a Scribd company logo
1 of 46
Type to enter a caption.
Review: GOUT
Sidney Erwin T. Manahan MD FPCP FPRA
Section of Rheumatology, East Avenue Medical Center
Disclosures
Pfizer (Celebrex)
Ajanta Philippines (Atenurix)
Coverage
How to diagnose?
How to manage acute gout?
How to prevent gout flares?
How to start and proceed with ULT?
Controversies
Is it GOUT?
Joint Pains
AND
Hyperuricemia
means GOUT?
Joint Inflammation
AND
The Gout, James Gillray 1799
Is it GOUT? 1977 ARA Classification
Criteria
Urate crystals in SF, OR
Urate crystals in suspected
tophus, OR
Any 6 of the following 12
>1 episode of acute arthritis
Maximal inflammation <24h
Monoarthritis
Joint redness
Podagra
Unilateral MTP1 attack
Unilateral tarsal jt attack
Suspected tophus
Hyperuricemia
Asymmetric jt swelling on XR
Subcortical cysts without
erosions on XR
Negative SF culture
Wallace SL, et al. Arthritis 1977; 20: 895-900.
Is it GOUT? 2014 Nijmegen score
NOT GOUT <4
Uncertain >4 but <8
GOUT >8
FEATURES Score
Male 2
Previous attack 2
Onset within 1 day 0.5
Joint redness 1
Podagra 2.5
HPN or >1 CV disease 1.5
SUA >5.88 mg/dl 3.5
Kienhorst LB, et al. Rheumatology (Oxford) 2014; 16: epub.
Developments in Imaging
Ultrasound - Tophus
Sen 0.65 / Spe 0.80
Ultrasound - DCT
Sen 0.80 / Spe 0.76
Dual Energy CT (DECT)
Sen 0.87 / Spe 0.76
Type to enter a caption. Type to enter a caption.
Type to enter a caption.
Is it GOUT? from 2015 onwards
2015 ACR EULAR Classification
Criteria
Clinical parameters (4)
Laboratory (2)
Imaging modalities (2)
Maximum score is 23
For gout, need a score >8
Neogi T, et al. Ann Rheum Dis 2015; 74: 1789-98.
ACR EULAR 2015 Gout
ENTRY CRITERION: At least one episode of pain, swelling or
tenderness in a peripheral joint or bursa
SUFFICIENT CRITERIA: Presence of MSU crystals in a symptomatic
joint, bursa or tophus
ACR EULAR 2015 Gout Criteria
JOINT INVOLVEMENT
Other joints/ polyarthritis (0)
Ankle/ mid foot (1)
MTP1 (2)
CHARACTERISTICS
Erythema
Can’t bear touch or pressure
Great difficulty ambulating
None present (0)
One present (1)
Two present (2)
All three present (3)
ACR EULAR 2015 Gout Criteria
EVIDENT TOPHUS
Absent (0)
Present (4)
TYPICAL EPISODE
Maximal pain <24h
Resolution <14 days
No symptoms between attacks
No typical episode (0)
One typical episode (1)
Recurrent typical episode (2)
ACR EULAR 2015 Gout Criteria
URIC ACID LEVELS
<4 mg/dl (-4)
4 - <6 mg/dl (0)
6 - <8 mg/dl (2)
8 - <10 mg/dl (3)
>10 mg/dl (4)
SYNOVIAL FLUID ANALYSIS
MSU negative (-2)
Not done (0)
DECT/ ULTRASOUND
Absent OR Not Done (0)
Present (4)
RADIOGRAPHS
Absent Or Not Done (0)
Present (4)
Performance of Criteria
CRITERIA Sensitivity Specificity
2015 ACR EULAR full 0.92 0.89
2015 ACR EULAR clinical 0.85 0.78
1977 ARA full 1.00 0.51
1977 ARA survey 0.84 0.62
Case A
68F consults for podagra of 2
days. She’s had several episodes
in the past with maximal sx in
12h, resolves in 1 week,
asymptomatic in between. PE
reveals warm, erythematous,
tender R MTP1.
SUA 8 mg/dl
ST swelling on radiographs
MTP1 2
3 Characteristics 3
Recurrent eps 2
No tophus 0
SUA 8mg/dl 3
SF not done 0
No DECT / US 0
No XR 0
Case B
56M consults for knee pain of 2
weeks duration. No prior
episodes. PE reveals a warm,
swollen, erythematous left knee
that is tender to touch. Knee is
kept in a flexed position.
SUA 9 mg/dl
ST swelling on radiographs
Knee 0
3 Characteristics 3
No typical episode 0
No tophus 0
SUA 9mg/dl 3
SF not done 0
No DECT / US 0
(-) Knee XR 0
Goals of GOUT Management
Acute Intercritical Chronic Tophaceous
Prevent further gout flares
Terminate an attack
Prevent
Complications
Reverse
Complications
Terminating ACUTE GOUT
VAS < 7/10 OR
few small joints OR
1-2 large joints
VAS > 7/10 OR
Polyarthritis OR
1-2 large joints
Monotherapy
Combination
Therapy
RESPONSE?
VAS >20% in <24H and >50% in >24H
RE-EVALUATE
DIAGNOSIS
Khan na D, et al. Arth Care & Res 2012: 64 (10): 1447-61.
Treatment Options: ACUTE GOUT
COLCHICINE NSAIDs STEROIDS
1 mg INITIALLY then 0.5 mg
AFTER 1 hour then
0.5 mg TID 12 hours later
Ibuprofen 2400 mg/d
Diclofenac 150 mg/d
Naproxen 1000 mg/d
Indomethacin 150 mg/d
Etoricoxib 120 mg/d
Celecoxib 400 mg/d
ALL FOR <8 DAYS
INTRA-ARTICULAR
INTRA-MUSCULAR
Prednisone 0.5-1 mkd for 5-
10 days
ACTH 25-40 IU SC
x 1-2 doses
Treatment Options: ACUTE GOUT
NSAIDs COLCHICINE Sys STEROIDS
IA Steroids AND any of the three
Considerations for TREATMENT
Condition Colchicine NSAIDs Steroids
CKD stage 3-5 πŸ‘Ž* πŸ‘Ž
Heart Failure πŸ‘Ž πŸ‘Ž
Liver Cirrhosis πŸ‘Ž πŸ‘Ž
Peptic Ulcer Disease πŸ‘Ž πŸ‘Ž**
Diabetes πŸ‘Ž
Infections πŸ‘Ž
Anticoagulants πŸ‘Ž πŸ‘Ž
* Colchicine avoided if GFR <10; reduced dose if GFR 15-30
** Consider COXIBs; Celecoxib + PPI if high risk PUD
Preventing GOUT ATTACKS
COLCHICINE NSAID STEROID
0.5 mg OD-BID Naproxen 250 mg BID Prednisone <10mg/d
6 months of NO FLARES and TARGET SUA
(traditional)
If non-tophaceous gout, 3 months of NO FLARES
and TARGET SUA
If tophaceous gout, 6 months of NO FLARES,
TARGET SUA and RESOLUTION OF ALL TOPHI
Indications for Starting ULT
After the second flare (EULAR 2017)
Presence of tophi
Presence of UA Nephrolithiases
Radiographic evidence of gout
Co-morbid conditions that would complicate
management of gout (CKD, CV disease)
SUA >11 mg/dl (SUA>8, mg/dl EULAR 2017)
What is our GOAL?
TARGET SUA
β€’ American College of
Rheumatology (ACR)
β€’ British Society of
Rheumatology (BSR)
β€’ European League Against
Rheumatism (EULAR)
β€’ Philippine Rheumatology
Association (PRA)
SYMPTOM FREE
β€’ American College of
Physicians (ACP)
Target for ULT
< 6 mg/dl
if no tophi
Reduces risk of gout
flares
< 5 mg/dl
if with tophi
Reduces risk of gout flares
Reduces tophus size (1 mm/mo)
Stone dissolution
? Improvement in renal function
When Do We Start ULT?
10 - 14 days AFTER the gout attack
resolves (PRA)
May be started DURING an acute attack
provided ADEQUATE anti-inflammatory
treatment is given (ACR)
25% chance of worsening, recurrent or
prolonged flare.
Treatment Options: ULT
Uricosurics
Xanthine Oxidase
Inhibitors (XOIs)
Uricase
Probenecid
Sulfinpyrazone
Benzbromarone
Lesinurad
Losartan
Fenofibrate
Amlodipine*
Allopurinol
Febuxostat
Pegloticase
Rasburicase
* Amlodipine showed uricosuric action in the setting of cyclosporine induced hyperuricemia
How do we proceed with ULT?
Start Allopurinol 100 mg OD
Increase by 100 mg/d
every 4 weeks until TARGET
Start Febuxostat 40 mg OD
Add uricosuric
Increase by 40 mg/d
every 2-4 weeks until
TARGET
Add uricosuric
Have you achieved your target SUA 2-4 weeks later?
Have you achieved your target SUA on follow up?
How do we proceed with ULT?
100 mg
200 mg
500 mg
300 mg
400 mg
600 mg
700 mg
800 mg
900 mg
40 mg
80 mg
120 mg
PNDF Drug
Non PNDF
Drug
Which is BETTER?
NO DIFFERENCE in
incidence of gout
flares, adverse events
and discontinuation
rates
Allopurinol 300 mg =
Febuxostat 40mg
ULT in the setting of CKD
ALLOPURINOL
Starting dose of 50 mg/d or 100
mg EOD when CKD stage 4-5
Titrate by 50mg every 4-5 weeks
Maximum dose is as tolerated by
patient’s kidney and liver
50% of dose given as
supplement after HD
FEBUXOSTAT
Starting dose of 20 mg/d when
eGFR <30 ml/min
Titrate by 20 mg every 4 weeks
Maximum dose 40-60 mg/d
Use not defined in HD
Can we give allopurinol > 300 mg/d
in patients with CKD?
Guarded YES.
EDUCATE patients of possible
adverse events
MONITOR for pruritus, rash,
increased LFTs, eosinophilia
Allopurinol Hypersensitivity Reactions
Interface between Rheumatology and Allergology
Spectrum of Allopurinol AEs
Median time: 3 weeks
90% occurred within 8-
9 weeks of starting
allopurinol
AHSSCAR
DRESS
SJS/
TENS
Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
Features of Allopurinol AEs
Reaction Liver Renal Fever
Eosin
ophili
a
Leucocytosis Others
Allopurinol
Hypersensitivity
Syndrome
Yes
Drug Reaction with
Eosinophilia and
Systemic Symptoms
Atypical
lymphocytosis
Inflammation of internal
organs (inc. interstitial
pneumonitis, pleuritis &
ARDS)
TENS/ SJS
Atypical lymphocytosis
generally do not occur
Sore throat, conjunctivitis,
arthralgia, GI or respiratory
tract may be affected
Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
Risk Factors for Allopurinol AEs
Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
Recent
initiation of
Allopurinol
HLA-B*5801
Dose
Renal function
Diuretic use
TIME GENETICS
DRUG
CONCENTRATION
Who are likely to have HLA B*5801
COMMON
Han Chinese (13.3 - 20.4%)
Korean (12.2%)
Thai (8.1%)
LESS COMMON
Japanese (0.61%)
European (1.5 - 5.2%)
Would you give him
Allopurinol?
Impact of Dose on AHS
Allopurinol - intolerant Allopurinol - tolerant
Mean Starting Dose 183.5 mg/d 112.2 mg/d
> 1.5 mg/ml/min Allopurinol 91% 36%
> 2 mg/ml/min Allopurinol 79% 53%
SUGGESTION: Start Allopurinol at 1.5 mg x ml/min GFR
Chung WH, et al. Ann Rheum Dis 2015: 74: 2157-64.
Diuretics Concerns in Gout
Known risk factor for AHS/
SCAR
Increase urate levels (HCTZ)
Increase oxypurinol levels
Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
Do we treat asymptomatic
hyperuricemia?
To reduce risk of gout, NO.
To prevent UA nephrolithiases, YES if SUA
>11 mg/dl.
To reduce CV events, need larger well
designed RCTs. (Allopurinol is still the
preferred drug, Febuxostat might increase
CV risks, review CARES)
To protect the kidneys, NO FURTHER
benefit after 1 year of use.
Do we still advise a low purine diet?
Type to enter a caption.
If a patient is able to strictly adhere to a low purine diet,
serum urate levels will only go down by 0.5-1 mg/dl.
Gout will make
a comeback!
Genes contribute
more to
hyperuricemia than
the food we eat.
Major TJ, et al. BMJ 2018;
363: k3951.
What food impacts on SUA
RAISE URIC ACID LEVELS LOWERS URIC ACID LEVELS
Beer
Liquor
Wine
Potatoes
Poultry
Softdrinks
Meat (beef, pork or lamb)
Eggs
Peanuts
Cold cereal
Skimmed milk
Cheese
Brown bread
Margarine
Non citrus fruit
Practical Dietary Advice
Weight loss if overweight/ obese
Limit alcohol intake to red wine
Avoid sugar sweetened
beverages (and anything with
corn syrup/ fructose)
Avoid food triggers if present
(until urate levels controlled).
Summary
Diagnosis of gout
Management tailored to stage of
disease
Discussed concerns over
allopurinol adverse events,
asymptomatic hyperuricemia
and dietary advice.
Post Report Quiz
For iOS users, scan the image using
your camera app.
For android users, scan the image
using the QR scanner of your Viber
app.
An internet connection is needed for
you to access the quiz.

More Related Content

What's hot

Seronegative spondyloarthropathies
Seronegative spondyloarthropathiesSeronegative spondyloarthropathies
Seronegative spondyloarthropathiesairwave12
Β 
Gout and pseudogout
Gout and pseudogoutGout and pseudogout
Gout and pseudogoutdrangelosmith
Β 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritisdrangelosmith
Β 
Reactive arthritis
Reactive arthritisReactive arthritis
Reactive arthritisSachin Giri
Β 
2010 ACR/EULAR Criteria for RA
2010 ACR/EULAR Criteria for RA2010 ACR/EULAR Criteria for RA
2010 ACR/EULAR Criteria for RAYounis I Munshi
Β 
Physical examination for gout
Physical examination for goutPhysical examination for gout
Physical examination for goutLaxchimi Ghanis
Β 
Approach to joint pain
Approach to joint painApproach to joint pain
Approach to joint painanoop r prasad
Β 
Rheumatoid Arthritis
Rheumatoid ArthritisRheumatoid Arthritis
Rheumatoid ArthritisGajanan Pandit
Β 
ARTHRITIS & RHEUMATOLOGY by DR K. DELE
ARTHRITIS & RHEUMATOLOGY by DR K. DELEARTHRITIS & RHEUMATOLOGY by DR K. DELE
ARTHRITIS & RHEUMATOLOGY by DR K. DELEKemi Dele-Ijagbulu
Β 
Splenomegaly : causes , clinical approach and examination
Splenomegaly : causes , clinical approach and examinationSplenomegaly : causes , clinical approach and examination
Splenomegaly : causes , clinical approach and examinationVasif Mayan
Β 
Liver abscess , case presentation
Liver abscess , case presentation  Liver abscess , case presentation
Liver abscess , case presentation Anupam Ghimire
Β 
Gout case presentation
Gout   case presentationGout   case presentation
Gout case presentationVignesh Gk
Β 
Approach To A Patient With Polyarthritis
Approach To A Patient With PolyarthritisApproach To A Patient With Polyarthritis
Approach To A Patient With PolyarthritisPramod Mahender
Β 
Rheumatoid arthritis
Rheumatoid arthritis Rheumatoid arthritis
Rheumatoid arthritis Harsh Chunara
Β 
[Int. med] approach to joint pain from SIMS Lahore
[Int. med] approach to joint pain from SIMS Lahore[Int. med] approach to joint pain from SIMS Lahore
[Int. med] approach to joint pain from SIMS LahoreMuhammad Ahmad
Β 
Gout and Hyperuricemia
Gout and HyperuricemiaGout and Hyperuricemia
Gout and HyperuricemiaArwa M. Amin
Β 

What's hot (20)

Seronegative spondyloarthropathies
Seronegative spondyloarthropathiesSeronegative spondyloarthropathies
Seronegative spondyloarthropathies
Β 
Gout and pseudogout
Gout and pseudogoutGout and pseudogout
Gout and pseudogout
Β 
SERO-NEGATIVE ARTHRITIS
SERO-NEGATIVE ARTHRITISSERO-NEGATIVE ARTHRITIS
SERO-NEGATIVE ARTHRITIS
Β 
Approach to arthritis
Approach to arthritisApproach to arthritis
Approach to arthritis
Β 
Osteoarthritis
OsteoarthritisOsteoarthritis
Osteoarthritis
Β 
Reactive arthritis
Reactive arthritisReactive arthritis
Reactive arthritis
Β 
2010 ACR/EULAR Criteria for RA
2010 ACR/EULAR Criteria for RA2010 ACR/EULAR Criteria for RA
2010 ACR/EULAR Criteria for RA
Β 
Physical examination for gout
Physical examination for goutPhysical examination for gout
Physical examination for gout
Β 
Approach to joint pain
Approach to joint painApproach to joint pain
Approach to joint pain
Β 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
Β 
Gout
GoutGout
Gout
Β 
Rheumatoid Arthritis
Rheumatoid ArthritisRheumatoid Arthritis
Rheumatoid Arthritis
Β 
ARTHRITIS & RHEUMATOLOGY by DR K. DELE
ARTHRITIS & RHEUMATOLOGY by DR K. DELEARTHRITIS & RHEUMATOLOGY by DR K. DELE
ARTHRITIS & RHEUMATOLOGY by DR K. DELE
Β 
Splenomegaly : causes , clinical approach and examination
Splenomegaly : causes , clinical approach and examinationSplenomegaly : causes , clinical approach and examination
Splenomegaly : causes , clinical approach and examination
Β 
Liver abscess , case presentation
Liver abscess , case presentation  Liver abscess , case presentation
Liver abscess , case presentation
Β 
Gout case presentation
Gout   case presentationGout   case presentation
Gout case presentation
Β 
Approach To A Patient With Polyarthritis
Approach To A Patient With PolyarthritisApproach To A Patient With Polyarthritis
Approach To A Patient With Polyarthritis
Β 
Rheumatoid arthritis
Rheumatoid arthritis Rheumatoid arthritis
Rheumatoid arthritis
Β 
[Int. med] approach to joint pain from SIMS Lahore
[Int. med] approach to joint pain from SIMS Lahore[Int. med] approach to joint pain from SIMS Lahore
[Int. med] approach to joint pain from SIMS Lahore
Β 
Gout and Hyperuricemia
Gout and HyperuricemiaGout and Hyperuricemia
Gout and Hyperuricemia
Β 

Similar to Gout Review for Residents

PPT KEL 1 hipertensi fater.id.en (2).pptx
PPT KEL 1 hipertensi fater.id.en (2).pptxPPT KEL 1 hipertensi fater.id.en (2).pptx
PPT KEL 1 hipertensi fater.id.en (2).pptxNurjanaAndris
Β 
Gout - all you need for primary care
Gout - all you need for primary careGout - all you need for primary care
Gout - all you need for primary careRonan Kavanagh
Β 
How to manage adverse events from oncologic treatments.pdf
How to manage adverse events from oncologic treatments.pdfHow to manage adverse events from oncologic treatments.pdf
How to manage adverse events from oncologic treatments.pdfLanceCatedral
Β 
Inflammatory Bowel Disease
Inflammatory Bowel DiseaseInflammatory Bowel Disease
Inflammatory Bowel DiseaseKehoeMaths
Β 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxDrHarsh Saxena
Β 
Oxaliplatin induced hypersensitivity reaction
Oxaliplatin induced hypersensitivity reactionOxaliplatin induced hypersensitivity reaction
Oxaliplatin induced hypersensitivity reactionChoying Chen
Β 
Rheumatoid arthritis and gout
Rheumatoid arthritis  and goutRheumatoid arthritis  and gout
Rheumatoid arthritis and goutSMS MEDICAL COLLEGE
Β 
Hemostasis Optimization.pptx
Hemostasis Optimization.pptxHemostasis Optimization.pptx
Hemostasis Optimization.pptxDr Arijit Guha
Β 
Gout, tophi and kidney disease
Gout, tophi and kidney diseaseGout, tophi and kidney disease
Gout, tophi and kidney diseaseSidney Erwin Manahan
Β 
Gout medications zagazig 2019
Gout medications zagazig 2019 Gout medications zagazig 2019
Gout medications zagazig 2019 SafwatElaraby
Β 
Voclosporin journal club
Voclosporin journal clubVoclosporin journal club
Voclosporin journal clubDr. Prem Mohan Jha
Β 
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...University Hospital Sharjah
Β 
Overview of drugs approved in 2011 dr.devang
Overview of drugs approved in 2011 dr.devangOverview of drugs approved in 2011 dr.devang
Overview of drugs approved in 2011 dr.devangDevang Parikh
Β 
Covid19 oct 2020
Covid19    oct 2020Covid19    oct 2020
Covid19 oct 2020Best Doctors
Β 
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASE
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASESAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASE
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASESaiDeepakS1
Β 
Allopurinol drug information
Allopurinol drug informationAllopurinol drug information
Allopurinol drug informationSneha Gogineni
Β 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorDerekRuzzo
Β 

Similar to Gout Review for Residents (20)

PPT KEL 1 hipertensi fater.id.en (2).pptx
PPT KEL 1 hipertensi fater.id.en (2).pptxPPT KEL 1 hipertensi fater.id.en (2).pptx
PPT KEL 1 hipertensi fater.id.en (2).pptx
Β 
Gout - all you need for primary care
Gout - all you need for primary careGout - all you need for primary care
Gout - all you need for primary care
Β 
2014 GSS Updates on Gout
2014 GSS Updates on Gout2014 GSS Updates on Gout
2014 GSS Updates on Gout
Β 
How to manage adverse events from oncologic treatments.pdf
How to manage adverse events from oncologic treatments.pdfHow to manage adverse events from oncologic treatments.pdf
How to manage adverse events from oncologic treatments.pdf
Β 
Inflammatory Bowel Disease
Inflammatory Bowel DiseaseInflammatory Bowel Disease
Inflammatory Bowel Disease
Β 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptx
Β 
Oxaliplatin induced hypersensitivity reaction
Oxaliplatin induced hypersensitivity reactionOxaliplatin induced hypersensitivity reaction
Oxaliplatin induced hypersensitivity reaction
Β 
Rheumatoid arthritis and gout
Rheumatoid arthritis  and goutRheumatoid arthritis  and gout
Rheumatoid arthritis and gout
Β 
Hemostasis Optimization.pptx
Hemostasis Optimization.pptxHemostasis Optimization.pptx
Hemostasis Optimization.pptx
Β 
Gout, tophi and kidney disease
Gout, tophi and kidney diseaseGout, tophi and kidney disease
Gout, tophi and kidney disease
Β 
Gout medications zagazig 2019
Gout medications zagazig 2019 Gout medications zagazig 2019
Gout medications zagazig 2019
Β 
Voclosporin journal club
Voclosporin journal clubVoclosporin journal club
Voclosporin journal club
Β 
Rational NSAID Use IM.pptx
Rational NSAID Use IM.pptxRational NSAID Use IM.pptx
Rational NSAID Use IM.pptx
Β 
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...
Gout 2017 by Prof. Professor Sukhbir Uppal Consultant in Medicine/Rheumatolog...
Β 
Overview of drugs approved in 2011 dr.devang
Overview of drugs approved in 2011 dr.devangOverview of drugs approved in 2011 dr.devang
Overview of drugs approved in 2011 dr.devang
Β 
Nephrotic syndrome.
Nephrotic syndrome.Nephrotic syndrome.
Nephrotic syndrome.
Β 
Covid19 oct 2020
Covid19    oct 2020Covid19    oct 2020
Covid19 oct 2020
Β 
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASE
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASESAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASE
SAI DEEPAK CASE STUDY ON CHRONIC KIDNEY DISEASE
Β 
Allopurinol drug information
Allopurinol drug informationAllopurinol drug information
Allopurinol drug information
Β 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
Β 

More from Sidney Erwin Manahan

Joint and Back Pain Approach.pptx
Joint and Back Pain Approach.pptxJoint and Back Pain Approach.pptx
Joint and Back Pain Approach.pptxSidney Erwin Manahan
Β 
Lupus Nephritis Guideline Review 2022
Lupus Nephritis Guideline Review 2022Lupus Nephritis Guideline Review 2022
Lupus Nephritis Guideline Review 2022Sidney Erwin Manahan
Β 
Treating Asymptomatic Hyperuricemia for Better CV Outcomes
Treating Asymptomatic Hyperuricemia for Better CV OutcomesTreating Asymptomatic Hyperuricemia for Better CV Outcomes
Treating Asymptomatic Hyperuricemia for Better CV OutcomesSidney Erwin Manahan
Β 
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Sidney Erwin Manahan
Β 
B Vitamins and musculoskeletal disease
B Vitamins and musculoskeletal diseaseB Vitamins and musculoskeletal disease
B Vitamins and musculoskeletal diseaseSidney Erwin Manahan
Β 
Updates to the Approach to Rheumatic Disease
Updates to the Approach to Rheumatic DiseaseUpdates to the Approach to Rheumatic Disease
Updates to the Approach to Rheumatic DiseaseSidney Erwin Manahan
Β 
Treatment Decisions in Osteoarthritis
Treatment Decisions in OsteoarthritisTreatment Decisions in Osteoarthritis
Treatment Decisions in OsteoarthritisSidney Erwin Manahan
Β 
Revisiting Gout: Guideline Updates PRA 2015
Revisiting Gout:  Guideline Updates PRA 2015Revisiting Gout:  Guideline Updates PRA 2015
Revisiting Gout: Guideline Updates PRA 2015Sidney Erwin Manahan
Β 
Novel Targets in Osteoarthritis Manahan SIG 11 2014
Novel Targets in Osteoarthritis Manahan SIG 11 2014Novel Targets in Osteoarthritis Manahan SIG 11 2014
Novel Targets in Osteoarthritis Manahan SIG 11 2014Sidney Erwin Manahan
Β 
Updates in Fibromyalgia: Diagnosis and Management
Updates in Fibromyalgia: Diagnosis and ManagementUpdates in Fibromyalgia: Diagnosis and Management
Updates in Fibromyalgia: Diagnosis and ManagementSidney Erwin Manahan
Β 
Acr 2012 updates and Philippine applicability
Acr 2012 updates and Philippine applicabilityAcr 2012 updates and Philippine applicability
Acr 2012 updates and Philippine applicabilitySidney Erwin Manahan
Β 
Challenges in Managing Takayasu Arteritis
Challenges in Managing Takayasu ArteritisChallenges in Managing Takayasu Arteritis
Challenges in Managing Takayasu ArteritisSidney Erwin Manahan
Β 
Updates in OA 2011 Post Grad
Updates in OA 2011 Post GradUpdates in OA 2011 Post Grad
Updates in OA 2011 Post GradSidney Erwin Manahan
Β 
Gout 2012: Updates to an Old Disease
Gout 2012: Updates to an Old DiseaseGout 2012: Updates to an Old Disease
Gout 2012: Updates to an Old DiseaseSidney Erwin Manahan
Β 

More from Sidney Erwin Manahan (16)

Joint and Back Pain Approach.pptx
Joint and Back Pain Approach.pptxJoint and Back Pain Approach.pptx
Joint and Back Pain Approach.pptx
Β 
Lupus Nephritis Guideline Review 2022
Lupus Nephritis Guideline Review 2022Lupus Nephritis Guideline Review 2022
Lupus Nephritis Guideline Review 2022
Β 
Treating Asymptomatic Hyperuricemia for Better CV Outcomes
Treating Asymptomatic Hyperuricemia for Better CV OutcomesTreating Asymptomatic Hyperuricemia for Better CV Outcomes
Treating Asymptomatic Hyperuricemia for Better CV Outcomes
Β 
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)
Β 
B Vitamins and musculoskeletal disease
B Vitamins and musculoskeletal diseaseB Vitamins and musculoskeletal disease
B Vitamins and musculoskeletal disease
Β 
Updates to the Approach to Rheumatic Disease
Updates to the Approach to Rheumatic DiseaseUpdates to the Approach to Rheumatic Disease
Updates to the Approach to Rheumatic Disease
Β 
Managing Lupus in Pregnancy
Managing Lupus in PregnancyManaging Lupus in Pregnancy
Managing Lupus in Pregnancy
Β 
Treatment Decisions in Osteoarthritis
Treatment Decisions in OsteoarthritisTreatment Decisions in Osteoarthritis
Treatment Decisions in Osteoarthritis
Β 
Revisiting Gout: Guideline Updates PRA 2015
Revisiting Gout:  Guideline Updates PRA 2015Revisiting Gout:  Guideline Updates PRA 2015
Revisiting Gout: Guideline Updates PRA 2015
Β 
Novel Targets in Osteoarthritis Manahan SIG 11 2014
Novel Targets in Osteoarthritis Manahan SIG 11 2014Novel Targets in Osteoarthritis Manahan SIG 11 2014
Novel Targets in Osteoarthritis Manahan SIG 11 2014
Β 
Updates in Fibromyalgia: Diagnosis and Management
Updates in Fibromyalgia: Diagnosis and ManagementUpdates in Fibromyalgia: Diagnosis and Management
Updates in Fibromyalgia: Diagnosis and Management
Β 
Acr 2012 updates and Philippine applicability
Acr 2012 updates and Philippine applicabilityAcr 2012 updates and Philippine applicability
Acr 2012 updates and Philippine applicability
Β 
Challenges in Managing Takayasu Arteritis
Challenges in Managing Takayasu ArteritisChallenges in Managing Takayasu Arteritis
Challenges in Managing Takayasu Arteritis
Β 
Updates in OA 2011 Post Grad
Updates in OA 2011 Post GradUpdates in OA 2011 Post Grad
Updates in OA 2011 Post Grad
Β 
Hyperuricemia in CKD
Hyperuricemia in CKDHyperuricemia in CKD
Hyperuricemia in CKD
Β 
Gout 2012: Updates to an Old Disease
Gout 2012: Updates to an Old DiseaseGout 2012: Updates to an Old Disease
Gout 2012: Updates to an Old Disease
Β 

Recently uploaded

Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
Β 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
Β 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
Β 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
Β 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
Β 
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...saminamagar
Β 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
Β 
call girls in munirka DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈ
call girls in munirka  DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈcall girls in munirka  DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈ
call girls in munirka DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈsaminamagar
Β 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
Β 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
Β 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
Β 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
Β 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
Β 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
Β 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
Β 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
Β 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
Β 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
Β 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
Β 

Recently uploaded (20)

Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Β 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
Β 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Β 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
Β 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
Β 
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Se...
Β 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
Β 
call girls in munirka DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈ
call girls in munirka  DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈcall girls in munirka  DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈ
call girls in munirka DELHI πŸ” >ΰΌ’9540349809 πŸ” genuine Escort Service πŸ”βœ”οΈβœ”οΈ
Β 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
Β 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
Β 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
Β 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
Β 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
Β 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Β 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
Β 
Epilepsy
EpilepsyEpilepsy
Epilepsy
Β 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
Β 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
Β 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
Β 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
Β 

Gout Review for Residents

  • 1. Type to enter a caption. Review: GOUT Sidney Erwin T. Manahan MD FPCP FPRA Section of Rheumatology, East Avenue Medical Center
  • 3. Coverage How to diagnose? How to manage acute gout? How to prevent gout flares? How to start and proceed with ULT? Controversies
  • 4. Is it GOUT? Joint Pains AND Hyperuricemia means GOUT? Joint Inflammation AND The Gout, James Gillray 1799
  • 5. Is it GOUT? 1977 ARA Classification Criteria Urate crystals in SF, OR Urate crystals in suspected tophus, OR Any 6 of the following 12 >1 episode of acute arthritis Maximal inflammation <24h Monoarthritis Joint redness Podagra Unilateral MTP1 attack Unilateral tarsal jt attack Suspected tophus Hyperuricemia Asymmetric jt swelling on XR Subcortical cysts without erosions on XR Negative SF culture Wallace SL, et al. Arthritis 1977; 20: 895-900.
  • 6. Is it GOUT? 2014 Nijmegen score NOT GOUT <4 Uncertain >4 but <8 GOUT >8 FEATURES Score Male 2 Previous attack 2 Onset within 1 day 0.5 Joint redness 1 Podagra 2.5 HPN or >1 CV disease 1.5 SUA >5.88 mg/dl 3.5 Kienhorst LB, et al. Rheumatology (Oxford) 2014; 16: epub.
  • 7. Developments in Imaging Ultrasound - Tophus Sen 0.65 / Spe 0.80 Ultrasound - DCT Sen 0.80 / Spe 0.76 Dual Energy CT (DECT) Sen 0.87 / Spe 0.76 Type to enter a caption. Type to enter a caption. Type to enter a caption.
  • 8. Is it GOUT? from 2015 onwards 2015 ACR EULAR Classification Criteria Clinical parameters (4) Laboratory (2) Imaging modalities (2) Maximum score is 23 For gout, need a score >8 Neogi T, et al. Ann Rheum Dis 2015; 74: 1789-98.
  • 9. ACR EULAR 2015 Gout ENTRY CRITERION: At least one episode of pain, swelling or tenderness in a peripheral joint or bursa SUFFICIENT CRITERIA: Presence of MSU crystals in a symptomatic joint, bursa or tophus
  • 10. ACR EULAR 2015 Gout Criteria JOINT INVOLVEMENT Other joints/ polyarthritis (0) Ankle/ mid foot (1) MTP1 (2) CHARACTERISTICS Erythema Can’t bear touch or pressure Great difficulty ambulating None present (0) One present (1) Two present (2) All three present (3)
  • 11. ACR EULAR 2015 Gout Criteria EVIDENT TOPHUS Absent (0) Present (4) TYPICAL EPISODE Maximal pain <24h Resolution <14 days No symptoms between attacks No typical episode (0) One typical episode (1) Recurrent typical episode (2)
  • 12. ACR EULAR 2015 Gout Criteria URIC ACID LEVELS <4 mg/dl (-4) 4 - <6 mg/dl (0) 6 - <8 mg/dl (2) 8 - <10 mg/dl (3) >10 mg/dl (4) SYNOVIAL FLUID ANALYSIS MSU negative (-2) Not done (0) DECT/ ULTRASOUND Absent OR Not Done (0) Present (4) RADIOGRAPHS Absent Or Not Done (0) Present (4)
  • 13. Performance of Criteria CRITERIA Sensitivity Specificity 2015 ACR EULAR full 0.92 0.89 2015 ACR EULAR clinical 0.85 0.78 1977 ARA full 1.00 0.51 1977 ARA survey 0.84 0.62
  • 14. Case A 68F consults for podagra of 2 days. She’s had several episodes in the past with maximal sx in 12h, resolves in 1 week, asymptomatic in between. PE reveals warm, erythematous, tender R MTP1. SUA 8 mg/dl ST swelling on radiographs MTP1 2 3 Characteristics 3 Recurrent eps 2 No tophus 0 SUA 8mg/dl 3 SF not done 0 No DECT / US 0 No XR 0
  • 15. Case B 56M consults for knee pain of 2 weeks duration. No prior episodes. PE reveals a warm, swollen, erythematous left knee that is tender to touch. Knee is kept in a flexed position. SUA 9 mg/dl ST swelling on radiographs Knee 0 3 Characteristics 3 No typical episode 0 No tophus 0 SUA 9mg/dl 3 SF not done 0 No DECT / US 0 (-) Knee XR 0
  • 16. Goals of GOUT Management Acute Intercritical Chronic Tophaceous Prevent further gout flares Terminate an attack Prevent Complications Reverse Complications
  • 17. Terminating ACUTE GOUT VAS < 7/10 OR few small joints OR 1-2 large joints VAS > 7/10 OR Polyarthritis OR 1-2 large joints Monotherapy Combination Therapy RESPONSE? VAS >20% in <24H and >50% in >24H RE-EVALUATE DIAGNOSIS Khan na D, et al. Arth Care & Res 2012: 64 (10): 1447-61.
  • 18. Treatment Options: ACUTE GOUT COLCHICINE NSAIDs STEROIDS 1 mg INITIALLY then 0.5 mg AFTER 1 hour then 0.5 mg TID 12 hours later Ibuprofen 2400 mg/d Diclofenac 150 mg/d Naproxen 1000 mg/d Indomethacin 150 mg/d Etoricoxib 120 mg/d Celecoxib 400 mg/d ALL FOR <8 DAYS INTRA-ARTICULAR INTRA-MUSCULAR Prednisone 0.5-1 mkd for 5- 10 days ACTH 25-40 IU SC x 1-2 doses
  • 19. Treatment Options: ACUTE GOUT NSAIDs COLCHICINE Sys STEROIDS IA Steroids AND any of the three
  • 20. Considerations for TREATMENT Condition Colchicine NSAIDs Steroids CKD stage 3-5 πŸ‘Ž* πŸ‘Ž Heart Failure πŸ‘Ž πŸ‘Ž Liver Cirrhosis πŸ‘Ž πŸ‘Ž Peptic Ulcer Disease πŸ‘Ž πŸ‘Ž** Diabetes πŸ‘Ž Infections πŸ‘Ž Anticoagulants πŸ‘Ž πŸ‘Ž * Colchicine avoided if GFR <10; reduced dose if GFR 15-30 ** Consider COXIBs; Celecoxib + PPI if high risk PUD
  • 21. Preventing GOUT ATTACKS COLCHICINE NSAID STEROID 0.5 mg OD-BID Naproxen 250 mg BID Prednisone <10mg/d 6 months of NO FLARES and TARGET SUA (traditional) If non-tophaceous gout, 3 months of NO FLARES and TARGET SUA If tophaceous gout, 6 months of NO FLARES, TARGET SUA and RESOLUTION OF ALL TOPHI
  • 22. Indications for Starting ULT After the second flare (EULAR 2017) Presence of tophi Presence of UA Nephrolithiases Radiographic evidence of gout Co-morbid conditions that would complicate management of gout (CKD, CV disease) SUA >11 mg/dl (SUA>8, mg/dl EULAR 2017)
  • 23. What is our GOAL? TARGET SUA β€’ American College of Rheumatology (ACR) β€’ British Society of Rheumatology (BSR) β€’ European League Against Rheumatism (EULAR) β€’ Philippine Rheumatology Association (PRA) SYMPTOM FREE β€’ American College of Physicians (ACP)
  • 24. Target for ULT < 6 mg/dl if no tophi Reduces risk of gout flares < 5 mg/dl if with tophi Reduces risk of gout flares Reduces tophus size (1 mm/mo) Stone dissolution ? Improvement in renal function
  • 25. When Do We Start ULT? 10 - 14 days AFTER the gout attack resolves (PRA) May be started DURING an acute attack provided ADEQUATE anti-inflammatory treatment is given (ACR) 25% chance of worsening, recurrent or prolonged flare.
  • 26. Treatment Options: ULT Uricosurics Xanthine Oxidase Inhibitors (XOIs) Uricase Probenecid Sulfinpyrazone Benzbromarone Lesinurad Losartan Fenofibrate Amlodipine* Allopurinol Febuxostat Pegloticase Rasburicase * Amlodipine showed uricosuric action in the setting of cyclosporine induced hyperuricemia
  • 27. How do we proceed with ULT? Start Allopurinol 100 mg OD Increase by 100 mg/d every 4 weeks until TARGET Start Febuxostat 40 mg OD Add uricosuric Increase by 40 mg/d every 2-4 weeks until TARGET Add uricosuric Have you achieved your target SUA 2-4 weeks later? Have you achieved your target SUA on follow up?
  • 28. How do we proceed with ULT? 100 mg 200 mg 500 mg 300 mg 400 mg 600 mg 700 mg 800 mg 900 mg 40 mg 80 mg 120 mg PNDF Drug Non PNDF Drug Which is BETTER? NO DIFFERENCE in incidence of gout flares, adverse events and discontinuation rates Allopurinol 300 mg = Febuxostat 40mg
  • 29. ULT in the setting of CKD ALLOPURINOL Starting dose of 50 mg/d or 100 mg EOD when CKD stage 4-5 Titrate by 50mg every 4-5 weeks Maximum dose is as tolerated by patient’s kidney and liver 50% of dose given as supplement after HD FEBUXOSTAT Starting dose of 20 mg/d when eGFR <30 ml/min Titrate by 20 mg every 4 weeks Maximum dose 40-60 mg/d Use not defined in HD
  • 30. Can we give allopurinol > 300 mg/d in patients with CKD? Guarded YES. EDUCATE patients of possible adverse events MONITOR for pruritus, rash, increased LFTs, eosinophilia
  • 31. Allopurinol Hypersensitivity Reactions Interface between Rheumatology and Allergology
  • 32. Spectrum of Allopurinol AEs Median time: 3 weeks 90% occurred within 8- 9 weeks of starting allopurinol AHSSCAR DRESS SJS/ TENS Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
  • 33. Features of Allopurinol AEs Reaction Liver Renal Fever Eosin ophili a Leucocytosis Others Allopurinol Hypersensitivity Syndrome Yes Drug Reaction with Eosinophilia and Systemic Symptoms Atypical lymphocytosis Inflammation of internal organs (inc. interstitial pneumonitis, pleuritis & ARDS) TENS/ SJS Atypical lymphocytosis generally do not occur Sore throat, conjunctivitis, arthralgia, GI or respiratory tract may be affected Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
  • 34. Risk Factors for Allopurinol AEs Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41. Recent initiation of Allopurinol HLA-B*5801 Dose Renal function Diuretic use TIME GENETICS DRUG CONCENTRATION
  • 35. Who are likely to have HLA B*5801 COMMON Han Chinese (13.3 - 20.4%) Korean (12.2%) Thai (8.1%) LESS COMMON Japanese (0.61%) European (1.5 - 5.2%) Would you give him Allopurinol?
  • 36. Impact of Dose on AHS Allopurinol - intolerant Allopurinol - tolerant Mean Starting Dose 183.5 mg/d 112.2 mg/d > 1.5 mg/ml/min Allopurinol 91% 36% > 2 mg/ml/min Allopurinol 79% 53% SUGGESTION: Start Allopurinol at 1.5 mg x ml/min GFR Chung WH, et al. Ann Rheum Dis 2015: 74: 2157-64.
  • 37. Diuretics Concerns in Gout Known risk factor for AHS/ SCAR Increase urate levels (HCTZ) Increase oxypurinol levels Stamp LK & Barclay ML. Rheumatology 2018; 57: i35-i41.
  • 38. Do we treat asymptomatic hyperuricemia? To reduce risk of gout, NO. To prevent UA nephrolithiases, YES if SUA >11 mg/dl. To reduce CV events, need larger well designed RCTs. (Allopurinol is still the preferred drug, Febuxostat might increase CV risks, review CARES) To protect the kidneys, NO FURTHER benefit after 1 year of use.
  • 39. Do we still advise a low purine diet? Type to enter a caption. If a patient is able to strictly adhere to a low purine diet, serum urate levels will only go down by 0.5-1 mg/dl.
  • 40. Gout will make a comeback!
  • 41. Genes contribute more to hyperuricemia than the food we eat. Major TJ, et al. BMJ 2018; 363: k3951.
  • 42.
  • 43. What food impacts on SUA RAISE URIC ACID LEVELS LOWERS URIC ACID LEVELS Beer Liquor Wine Potatoes Poultry Softdrinks Meat (beef, pork or lamb) Eggs Peanuts Cold cereal Skimmed milk Cheese Brown bread Margarine Non citrus fruit
  • 44. Practical Dietary Advice Weight loss if overweight/ obese Limit alcohol intake to red wine Avoid sugar sweetened beverages (and anything with corn syrup/ fructose) Avoid food triggers if present (until urate levels controlled).
  • 45. Summary Diagnosis of gout Management tailored to stage of disease Discussed concerns over allopurinol adverse events, asymptomatic hyperuricemia and dietary advice.
  • 46. Post Report Quiz For iOS users, scan the image using your camera app. For android users, scan the image using the QR scanner of your Viber app. An internet connection is needed for you to access the quiz.